Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Propranolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 8/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 7/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 6/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | HTR2C | P28335 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 4/20 | 1.00 |
| ▸ | HTR2A | P28223 | 3/20 | 1.00 |
| ▸ | HTR6 | P50406 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.97 |
| ▸ | NR2E1 | Q9Y466 | 5/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propranolol SCHEMBL9064508 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SIGMAR1ALDH1A1 | |
| Propranolol SCHEMBL29349844 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SIGMAR1ALDH1A1 | |
| Dexpropranolol SCHEMBL610656 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SIGMAR1ALDH1A1 | |
| Propranolol SCHEMBL17838091 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SIGMAR1ALDH1A1 | |
| Propranolol SCHEMBL41688 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SIGMAR1ALDH1A1 | |
| Levopropranolol SCHEMBL41689 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SIGMAR1ALDH1A1 | |
| Dexpropranolol SCHEMBL30309315 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SIGMAR1ALDH1A1 | |
| Levopropranolol SCHEMBL30530984 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SIGMAR1ALDH1A1 | |
| Propranolol SCHEMBL9183224 | 0.99 | ADRB2 (0.97) | ADRB2ADRB1ADRB3SIGMAR1ALDH1A1 | |
| Propranolol SCHEMBL7397696 | 0.99 | ADRB2 (0.97) | ADRB2ADRB1ADRB3SIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170196901-A1 | COMBINATION DRUG THERAPIES FOR CANCER AND METHODS OF MAKING AND USING THEM | VICUS THERAPEUTICS LLC (US) | 2017-07-13 | — | — | US | claimed |
| EP-1456670-B8 | METHODS RELATING TO TREATMENT OF ATHEROSCLEROSIS | CAMBRIDGE THERANOSTICS LTD (GB) | 2011-04-27 | — | — | EP | disclosed |
| EP-1456670-B1 | METHODS RELATING TO TREATMENT OF ATHEROSCLEROSIS | CAMBRIDGE THERANOSTICS LTD (GB) | 2009-07-15 | — | — | EP | disclosed |
| EP-1454140-B1 | DIAGNOSIS AND TREATMENT OF ATHEROSCLEROSIS | CAMBRIDGE THERANOSTICS LTD (GB) | 2009-07-08 | — | — | EP | disclosed |
| US-7504226-B2 | Methods relating to treatment of atherosclerosis | CAMBRIDGE THERANOSTICS LTD. (GB) | 2009-03-17 | — | — | US | disclosed |
| US-7419657-B2 | Reducing antibody-mediated lipid peroxidation activity in vascular systems; idiotypic antibodies; chlamydia pneumoniae vaccines | CAMBRIDGE THERANOSTICS LTD. (GB) | 2008-09-02 | — | — | US | disclosed |
| US-7148028-B2 | Methods and means relating to atherosclerosis | CAMBRIDGE THERANOSTICS LTD. (GB) | 2006-12-12 | — | — | US | disclosed |
| EP-1456670-A2 | METHODS RELATING TO TREATMENT OF ATHEROSCLEROSIS | Cambridge Theranostics Ltd. (GB) | 2004-09-15 | — | — | EP | disclosed |
| EP-1454140-A2 | DIAGNOSIS AND TREATMENT OF ATHEROSCLEROSIS | Cambridge Theranostics Ltd. (GB) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003019198-A2 | METHODS RELATING TO TREATMENT OF ATHEROSCLEROSIS | CAMBRIDGE THERANOSTICS LTD (GB) | 2003-03-06 | — | — | WO | disclosed |
| WO-2003019196-A2 | DIAGNOSIS AND TREATMENT OF ATHEROSCLEROSIS | CAMBRIDGE THERANOSTICS LTD (GB) | 2003-03-06 | — | — | WO | disclosed |
| US-6014631-A | Computer implemented patient medication review system and process for the managed care, health care and/or pharmacy industry | MERCK-MEDCO MANAGED CARE, LLC (US) | 2000-01-11 | — | — | US | disclosed |
| EP-0460064-A4 | THERAPEUTIC AEROSOL FORMULATIONS | — | 1992-04-01 | — | — | EP | disclosed |
| EP-0460064-A1 | THERAPEUTIC AEROSOL FORMULATIONS | RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1991-12-11 | — | — | EP | disclosed |
| WO-1990009781-A1 | THERAPEUTIC AEROSOL FORMULATIONS | RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1990-09-07 | — | — | WO | disclosed |